| Date | Title | Description |
| 12.08.2026 | Ainnocence's AINN-P1 Demonstrates Efficient Protein Prediction and Antibody Engineering | Transformer all-to-all attention (left) requires n² connections; mLSTM recurrent state passing (right) requires n steps, with a memory footprint that does not grow with sequence length.
Left: per-category performance, with AINN-P1 leading o... |
| 03.08.2026 | Ainnocence Shows Its Protein Foundation Model Improves Antibody-Antigen Affinity Ranking by 28% - From Sequence Alone | Mean five-fold cross-validated Spearman ρ for antibody-antigen ΔΔG ranking. All configurations use identical data and folds. Source: (Wang et al., 2026)
Representative High-Yield Antibody Discovery Campaigns on SentinusAI®
Ainnocence’s foun... |
| 20.07.2026 | Ainnocence Reports 91.4% Success Across 58 Antibody Affinity Maturation Campaigns, Opens 28-Program Biologics Pipeline | Structure-free AI platform delivers picomolar leads while cutting wet-lab validation to 20-50 samples per round
The number that matters to a partner is not how many molecules our model can score, it is how many they have to make”
— Dr. Luro... |
| 12.06.2026 | Ainnocence Brings Its Protein, Antibody and Peptide AI Models to Production as Secure, On-Demand APIs | Three proprietary models: AINN-P1, AINN-Basemodel, AINN-Peptide are available as secure on-demand APIs that integrate directly into existing discovery pipelines
Secure APIs for AINN-P1 and our peptide platform let partners access our founda... |
| 15.04.2026 | Ainnocence PeptideAI Platform screens 3.2M peptides with 90%+ accuracy in activity and therapeutic property predictions | PeptideAI® designs next-generation peptide therapeutics with enhanced stability, selectivity, and bioavailability
Foundation model-powered dual-module system establishes a new performance benchmark for AI-driven peptide drug discovery
By co... |
| 30.03.2026 | Ainnocence's CarbonAI®, a Proprietary AI Engine for De Novo Small-Molecule and PROTAC Design and Optimization | Platform screens up to 10 billion compounds in hours, delivering wet-lab-ready candidates in weeks without requiring 3D protein structures
CarbonAI® was designed from the ground to solve that problem. By working directly from sequence, we e... |
| 25.03.2026 | SentinusAI® Goes Live: Ainnocence’s AI Platform Turns Sequence Data Into Discovery Decisions in Days | The AI platform for therapeutic antibody and biologics discovery is now open for subscription.
SAN FRANCISCO , CA, UNITED STATES, March 25, 2026 /EINPresswire.com/ -- The Challenge
Therapeutic antibody development still depends heavily on s... |
| 06.03.2026 | Ainnocence Calls for Collaboration to Deploy AI-Driven Antibody Discovery Against World’s Deadliest Infectious Diseases | AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains
A Study shows mutation-resistant antibodies with 269×affinity, a proof point for CEPI’s 100 Days Mission and closing the therapeutic gap for 2... |
| 14.01.2026 | How sequence-based AI achieve whole genome screening for billions of small molecule and antibody candidates in hours | Featured in C&EN: Discover how sequence-based AI is transforming drug discovery, accelerating and broadening the search for new therapeutics
Destructed Drug Discovery: Sequence-Based AI for Rapid Evaluation of Small Molecules and Antibo... |
| 13.01.2026 | Ainnocence and Phase Advance Enter Industry-First AI Collab to Reduce Drug Development Timeline and Clinical Trial Risk | Phase Advance Logo
Ainnocence Logo
Dr. Tawanda Gumbo, Phase Advance CEO And Dr. Lurong Pan, Ainnocence CEO
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for i... |
| 09.01.2026 | NatmolAI™: Computational Expansion and Optimization of Natural-Product Chemical Space | NatmolAI™, Natural Molecule AI Engine
Our goal with NatmolAI™ is not to replace natural products, but to understand and extend them”
— Dr. Lurong Pan, CEO of Ainnocence
SAN FRANCISCO , CA, UNITED STATES, January 8, 2026 /EINPresswire.com/ -... |
| 01.01.2026 | Beauty Engineered: Ainnocence Launches CosmeticAI™ to Accelerate AI-Driven Innovation in Skincare and Beauty Products | Our goal with CosmeticAI™ was to make cosmetic ingredient development predictable rather than exploratory”
— Dr. Lurong Pan, CEO of Ainnocence
SAN FRANSICO, CA, UNITED STATES, January 1, 2026 /EINPresswire.com/ -- Ainnocence, a next-generat... |
| 19.12.2025 | AI Meets the Formula: Predictive Intelligence Redefines Chemical Design and Manufacturing | Ainnocence’s FormulaAI™ platform for sequence-based chemical formulation intelligence, enabling in silico performance prediction, process optimization and scale-up assessment.
FormulaAI™, an AI-based platform that brings predictive modeling... |
| 23.10.2025 | Antibody Design at Lightning Speed: AI-Driven Precision for Complex Targets | Ainnocence’s next-generation AI platform revolutionizes biologics discovery, achieving unprecedented scale, precision and speed in antibody and protein design.
Our AI platform brings protein and antibody design into a new era”
— Dr. Lurong ... |
| 25.09.2025 | Redefining Chemistry: How AI Shrinks Small-Molecule Discovery from Years to Weeks | Ainnocence’s CarbonAI® Platform for AI-Powered Small Molecule Drug Design — Enabling De Novo Generation, Lead Optimization, and Off-Target Prediction Without Structural Data
Chemistry shouldn’t take years to show you what’s possible”
— Dr. ... |
| 23.08.2025 | Ainnocence Achieves New Milestone with Protein Foundation Models | The baseline numbers are from the July 2025 ProteinGym zero-shot leaderboard; Ainnocence values are few-shot results reported below.
Proprietary sequence-first model rivals and in key areas surpasses the leading ProteinGym sequence-only bas... |
| 27.06.2025 | Ainnocence Launches BioSynthAI Platform for AI-Driven Synthetic Biology Product Discovery | Ainnocence’s BioSynthAI™ Synthetic Biology Engine — Accelerating Gene Design, Strain Optimization, and Bioprocess Control for Next-Generation Biomanufacturing
We are committed to advancing synthetic biology through the power of AI... BioSyn... |
| 08.05.2025 | Ainnocence Unveils Core Challenges Undermining AI-Driven Small-Molecule Drug Discovery | Ainnocence’s CarbonAI® Platform for AI-Powered Small Molecule Drug Design — Enabling De Novo Generation, Lead Optimization, and Off-Target Prediction Without Structural Data
How current methodologies fail to address critical challenges in e... |
| 14.04.2025 | Obatala Sciences and Ainnocence Announce Partnership to Transform Drug Discovery Through AI and Human Biological Models | MOUNTAIN VIEW, CA, UNITED STATES, April 14, 2025 /EINPresswire.com/ -- Highlights:
• Obatala Sciences and Ainnocence’s groundbreaking partnership addresses the FDA’s recent call for human-relevant methods for new drug development.
• The par... |
| 18.02.2025 | Ainnocence Achieves 10,000x Reduction in Computational Cost for Protein Design Without 3D Modeling | We’ve enabled an AI-driven process that efficiently mimics natural evolution—delivering results in hours instead of months, using just a single GPU.”
— Dr. Lurong Pan, CEO
SAN FRANCISCO, CA, UNITED STATES, February 18, 2025 /EINPresswire.co... |
| 29.01.2025 | Ainnocence Demonstrates Breakthrough AI Technology for Rapid Pandemic Response | SAN FRANCISCO, CA, UNITED STATES, January 29, 2025 /EINPresswire.com/ -- Ainnocence has achieved significant milestones in applying artificial intelligence to accelerate antibody discovery for pandemic preparedness, demonstrating unpreceden... |
| 25.11.2024 | AI Breakthrough Ushers in New Era of Personalized Medicine | SAN FRANCISCO, CA, UNITED STATES, November 25, 2024 /EINPresswire.com/ -- AI Biotechnology company Ainnocence is transforming healthcare through AI-driven advances in antibody, cell, and gene therapy design. Their proprietary third-generati... |
| 28.10.2024 | Revolutionizing Molecular Design beyond 3D modeling: Innovative R&D in Protein Language Models Unlocks New Frontiers | SAN FRANCISCO, CA, UNITED STATES, October 28, 2024 /EINPresswire.com/ -- Ainnocence, a pioneering AI-driven biotech company, is pushing the boundaries of molecular design with its next-generation protein engineering platform, setting a new ... |
| 07.10.2024 | Ainnocence Unveils Advanced AAV Design Services to Revolutionize Gene Therapy | SAN FRANCISCO, CA, UNITED STATES, October 7, 2024 /EINPresswire.com/ -- Ainnocence, a next-generation biotech company, is proud to announce the launch of its cutting-edge AAV (Adeno-Associated Virus) design services, powered by the Sentinus... |
| 03.09.2024 | AINNOCENCE LAUNCHES CellulaAI™: A Pioneering AI Engine to Revolutionize CAR-T Therapy | CellulaAI™, an innovative AI engine designed to transform the landscape of CAR-T therapy.
BIRMINGHAM, ALABAMA, UNITED STATES, September 3, 2024 /EINPresswire.com/ -- Ainnocence Inc., a leader in AI-driven biotech solutions, is proud to anno... |
| 05.08.2024 | Ainnocence Unveils SentinusAI®: Revolutionizing Antibody Design, Conquering Undruggable Targets, Rescuing Failed Trials | Revolutionizing drug discovery with our next-generation, self-evolving AI platform: SentinusAI®
Transforming Cancer Immunotherapies with AI-Driven Discovery and Optimization
SAN FRANCISCO, CALIFORNIA, UNITED STATES, August 5, 2024 /EINPress... |
| 06.05.2024 | Ainnocence Embraces Green AI and Animal-Free Drug Screening: A Dual Commitment to Sustainable and Ethical Innovation | SAN FRANCISCO, CALIFORNIA, U.S., May 6, 2024 /EINPresswire.com/ -- Ainnocence is proud to announce its strategic focus on highly sustainable and ethical applications in AI and biotechnology. With its commitment to Green AI and animal free d... |
